Company news: PhRMA, Amgen

Share this article:
A report by PhRMA suggests that the industry is looking at a robust pipeline. Among the trade group's findings: more than 5,000 new medications are being studied and 70% are “potential first-in-class medicines,” meaning a high potential for patent-loss replacements. The research, however, is not necessarily focused solely on broad-based applications: the interest group said that rare diseases, for example, continue to garner attention, with about 140 potential medicines being researched in the past decade, compared to 64 twenty years ago.

Clinical trial results indicate Amgen's anemia drug Aranesp is not a help for heart failure patients, reported Forbes. The Phase III testing started in 2006 with 2,278 patients, and today's announcement indicates the results missed the primary endpoint. Separately, the company said it will build a $200 million new manufacturing plant in Singapore for monoclonal antibodies.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.